ZENUZOLAC

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	RACEMIC
Molecular Formula	C11H11NO3
Molecular Weight	205.2099
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of ZENUZOLAC

Structure Search

SMILES

OC(=O)CC1CC(=NO1)C2=CC=CC=C2

InChI

InChIKey=MUFJHYRCIHHATF-UHFFFAOYSA-N

InChI=1S/C11H11NO3/c13-11(14)7-9-6-10(12-15-9)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,14)

HIDE SMILES / InChI

Molecular Formula	C11H11NO3
Molecular Weight	205.2099
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:37:14 UTC 2023` Edited by `admin` on `Sat Dec 16 11:37:14 UTC 2023`
Record UNII	AKT814N13R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZENUZOLAC

Official Name

English

GLS 1027 [WHO-DD]

Common Name

English

GIT-027

Code

English

(S,R)-3-PHENYL-4,5-DIHYDRO-5-ISOXASOLE ACETIC ACID

Systematic Name

English

GLS-1027

Code

English

VGX-1027

Code

English

VGX1027

Code

English

2-ISOXAZOLINE-5-ACETIC ACID, 3-PHENYL-

Systematic Name

English

4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID

Systematic Name

English

GLS1027

Code

English

5-ISOXAZOLEACETIC ACID, 4,5-DIHYDRO-3-PHENYL-

Systematic Name

English

zenuzolac [INN]

Common Name

English

GIT-27

Code

English

Code System Code Type Description

NCI_THESAURUS

C184883

Created by admin on Sat Dec 16 11:37:14 UTC 2023 , Edited by admin on Sat Dec 16 11:37:14 UTC 2023

PRIMARY

WIKIPEDIA

VGX-1027

Created by admin on Sat Dec 16 11:37:14 UTC 2023 , Edited by admin on Sat Dec 16 11:37:14 UTC 2023

PRIMARY

MANUFACTURER PRODUCT INFORMATION

VGX-1027

Created by admin on Sat Dec 16 11:37:14 UTC 2023 , Edited by admin on Sat Dec 16 11:37:14 UTC 2023

PRIMARY

Biochem/physiol Actions: VGX-1027 is a potent nitric oxide-donating immunomodulatory compound, which markedly decreased the cumulative incidence of diabetes and insulitis in NOD mice model with spontaneous or accelerated forms of diabetes induced either by injection of cyclophosphamide or by transfer of spleen cells from acutely diabetic syngeneic donors.

EPA CompTox

DTXSID50445023

Created by admin on Sat Dec 16 11:37:14 UTC 2023 , Edited by admin on Sat Dec 16 11:37:14 UTC 2023

PRIMARY

SMS_ID

300000036069

Created by admin on Sat Dec 16 11:37:14 UTC 2023 , Edited by admin on Sat Dec 16 11:37:14 UTC 2023

PRIMARY

INN

12006

Created by admin on Sat Dec 16 11:37:14 UTC 2023 , Edited by admin on Sat Dec 16 11:37:14 UTC 2023

PRIMARY

FDA UNII

AKT814N13R

Created by admin on Sat Dec 16 11:37:14 UTC 2023 , Edited by admin on Sat Dec 16 11:37:14 UTC 2023

PRIMARY

PUBCHEM

10798271

Created by admin on Sat Dec 16 11:37:14 UTC 2023 , Edited by admin on Sat Dec 16 11:37:14 UTC 2023

PRIMARY

CAS

6501-72-0

Created by admin on Sat Dec 16 11:37:14 UTC 2023 , Edited by admin on Sat Dec 16 11:37:14 UTC 2023

PRIMARY

ChEMBL

CHEMBL1320667

Created by admin on Sat Dec 16 11:37:14 UTC 2023 , Edited by admin on Sat Dec 16 11:37:14 UTC 2023

PRIMARY

Related Record Type Details


					AKT814N13R

ZENUZOLAC

ACTIVE MOIETY

Comments:

Class: Anti-inflammatory, Isoxazole, Small molecule; Mechanism of Action: NF-kappa B inhibitor, P38 mitogen-activated protein kinase inhibitor; Highest Development Phase: Phase I for Rheumatoid arthritis, Type 1 diabetes mellitus, Preclinical for Ulcerative colitis, Uveitis; Most Recent Events: 28 May 2010 Preparation for phase II trials of VGX 1027 is still underway for type 1 Diabetes mellitus and Rheumatoid arthritis in USA, 14 May 2010 Inovio Biomedical is now called Inovio Pharmaceuticals, 01 May 2010 Preclinical trials in Ulcerative colitis in USA (PO)

Amount: